Original Article

Patients and Health Care Providers Identify Important Outcomes for Research on Pregnancy and Heart Disease

Chelsea Hall, BScH, a,b and Rohan D. D’Souza, MD, PhD, FRCOG b,c

a Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
b Department of Obstetrics and Gynaecology, Division of Maternal-Fetal Medicine, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
c Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada

ABSTRACT

Background: A core outcome set for studies on cardiac disease in pregnancy is being developed. Incorporating perspectives of patients and health care providers (HCPs) is an essential step in developing this core outcome set, and eliciting these outcomes is the objective of this study.

Methods: We interviewed pregnant women with heart disease, family members, and HCPs, until data saturation was attained. Participants were asked to share experiences and perspectives, and comment on outcomes they deemed important. Interviews were recorded and

It is estimated that 1%-4% of all pregnancies are complicated by congenital or acquired cardiac disease. Despite advances in the management of these pregnancies, cardiac disease remains a significant cause of maternal and perinatal morbidity and mortality in both high- and low-income countries. In the past 2 decades, there has been a surge of well-designed prospective studies to address unanswered questions relating to the care of these women, with a view to developing appropriate guidelines. We conducted a systematic review, to determine variations in outcome reporting in studies on cardiac disease and pregnancy, and to determine the distribution of these outcomes by the 5 core outcome areas—mortality, clinical/physiological, life impact/functioning, resource use, and adverse events—as classified by a recently published taxonomy of medical outcomes. This systematic review identified 148 distinct outcomes, reported in 409 prospective studies on pregnancy and heart disease, published between 1980 and 2018 (unpublished data, 2020). Not only were we able to show considerable variation with regard to outcome reporting and measurement in these studies, but also that most reported outcomes were in the "clinical/physiological" and "adverse effects" core outcome areas (n = 139, 94%), with little-to-no emphasis on outcomes related to resource use (n = 3, 2%) or life impact/functioning (n = 0). In fact, patient-reported outcomes (PROs), defined as "any report of the status of a patient’s health condition that comes directly from the patient, without interpretation of the patient’s response by a clinician or anyone else," were seldom reported in studies on pregnancy and cardiac disease.

International initiatives such as Core Outcome Measures in Effectiveness Trials (COMET) have proposed the development of core outcome sets—a minimum standardized set of outcomes obtained through input from patients and other stakeholders involved in their care—as a solution to this problem of outcome reporting in clinical trials. A key feature of core outcome sets is the incorporation of patient and stakeholder input in determining what outcomes should be measured in future clinical trials. The development of a core outcome set for studies on cardiac disease in pregnancy (COSCarP) is currently underway. This 5-step process aims to arrive at consensus from a group of international stakeholders on a final set of outcomes that should be reported on all future studies on cardiac disease and pregnancy. The systematic review alluded to earlier is the first of these steps and represents outcomes considered important to researchers.
transcribed verbatim, and interpretive analysis was used to translate experiences into measurable outcomes. These were classified under 5 core outcome areas, based on a taxonomy of outcomes for medical research. A comparison of the distribution of outcomes within outcome areas, between patients and HCPs, and between interviews and published literature is presented.

**Results:** We obtained 17 outcomes from 13 patients and 3 family members, mostly related to general wellness of the baby, congenital anomalies, mental health, and health care delivery; and 45 outcomes from 10 HCPs, which were mostly clinical. Outcomes in published literature when compared with participants interview put greater emphasis on clinical outcomes (94% vs 76.5%, \( P = 0.03 \)) and limited emphasis on life impact (0% vs 17.6%, \( P < 0.001 \)).

**Conclusions:** Although clinical outcomes are the main focus of published research in heart disease and pregnancy, patients and HCPs emphasize the importance of outcomes related to general maternal and fetal well-being and life impact, which are seldom reported. Including these outcomes in future studies is essential to facilitating patient-centred care for pregnant women with cardiac disease.

in the field. The second step involves the elicitation of outcomes from patients and stakeholders. Although a systematic review summarizing the qualitative research on the topic identified 11 studies highlighting the experiences and perceptions of women with cardiac disease in pregnancy, none of these were aimed at eliciting outcomes deemed important to these patients during pregnancy and the postpartum period. We therefore conducted this study with the primary aim of eliciting outcomes from pregnant women with cardiac disease, their family members and health care professionals (HCPs) involved in their care, to inform the development of COSCarP, and inform future research in the area. Our study’s secondary aims were to compare and contrast outcomes considered important by pregnant women and family members vs HCPs, and those obtained from this study, with those previously reported in the literature.

**Methods**

**Study participants and recruitment**

This study was approved by the Mount Sinai Hospital Research Ethics Board (REB#18-0126-E). Between July and August 2018, pregnant women with congenital or acquired cardiac disease and their family members were recruited from the cardiac disease in pregnancy clinic of the Special Pregnancy Program at Mount Sinai Hospital in Toronto, Canada. Patients were eligible to participate if they had a congenital or acquired cardiac condition, as identified from their medical records. Family members most involved in medical decision making, who attended the clinic appointments, were also invited to participate in interviews. Proficiency in English was a requirement for both patients and family members to participate in interviews. Patient lists were reviewed before the clinic visit, and all patients who met the eligibility criteria were directly approached in clinic, by a study investigator, not involved in the clinical care of the patients. The investigator explained the basis of the study and answered any questions they may have had, and then allowed them and their family members to decide whether they would like to participate. No direct invites to eligible patients were sent out. Patients and their family members who expressed interest in participating in the study were given the option of being interviewed either in person or over the telephone. HCPs were contacted through e-mail, via contact lists assembled by the study investigators. HCPs were eligible for inclusion if they cared for pregnant women with cardiac disease, in a clinical context. Sampling was purposive to ensure diverse representation of patients in terms of the nature of the cardiac condition, and the inclusion of HCPs from different countries and of various clinical disciplines involved in the care of pregnant patients with cardiac disease. Decisions with regard to sampling were made by the study’s lead investigator. Recruitment was continued until data saturation—the point at which no new outcomes were identified in 2 successive interviews—was attained.

**Interview process**

The COSCarP project is being conducted under the auspices of the Outcome Reporting in Obstetric Studies (OROS) group, an international collaboration led by the University of Toronto, comprising clinicians, qualitative researchers, graduate students, medical students, and research assistants.
committed to the cause of ensuring standardization and comprehensiveness of outcome reporting in obstetric studies. The OROS group is currently overseeing the development of 9 core outcome sets, while training graduate and medical students in various aspects of core outcome set development, including the conduct of stakeholder interviews. So as to avoid the problem of power balance between patients and physicians, interviews for this study were conducted by the medical student, with no role in the clinical care of the patient. This student who is part of the OROS group has not only received instruction on the conduct of interviews, pertinent to the elicitation of outcomes, but also worked under the supervision of experts and fellow graduate students who are proficient in the conduct of interviews and in interpretive analysis. She was also involved in the development of the study protocol and interview guides,6 and co-authored a meta-synthesis of interviews on patients with obesity.10

At the commencement of each interview, the interviewer explained the objective and nature of the study, and obtained verbal (phone interviews) or written (in-person interviews) consent. An optional questionnaire was provided to participants along with the consent form, to obtain information on age, parity, ethnicity, household income, and other demographic information, which could have influenced responses. Interviews were scheduled to last 60 minutes and were audio-recorded for later analysis.

Interviews were conducted in a semistructured format. The interviewer followed a written script specific to either patients/family members or HCPs with several open-ended questions. The interview guides for patients and care providers are presented as Supplemental Methods S1 and S2. Although the interviews had a semistructured format with a focus on eliciting outcomes related to their care, we encouraged participants to talk freely about their experiences and perspectives, acknowledging that the concept of outcomes can be difficult to explain and discuss with those who do not work and think in a health intervention context.11,12 However, the interviewer was trained to redirect and focus the participant on eliciting outcomes when deemed necessary, and to ensure that the participant focussed on both individuals of the mother-fetus dyad.13 Interviews were audio-recorded and transcribed verbatim, by a medical transcriber.

Analysis

Our analytical methodology was derived from interpretive evidence synthesis methods19 and relied on our ability to recognize and extract cardiology- and pregnancy-related outcomes. Although thematic analysis offers insight into experiences and perspectives, it does not enable the elicitation of potentially measurable outcomes that would inform the development of a core outcome set or inform future (quantitative) clinical research. Because this was the primary intent of this study, we performed interpretive analysis, wherein we translated experiences and perspectives obtained through interviews into outcomes as previously described.14 A single reviewer (CH) analyzed the transcribed interviews, identifying outcomes, if directly reported, and using interpretive analysis to extract outcomes from the experiences or perspective shared by participants, particularly with the patients and family member interviews. Where there was uncertainty surrounding whether or not a section of an interview could be accurately translated into outcomes, this was discussed with a second reviewer (RDD). Outcomes were grouped into maternal vs fetal/neonatal outcomes and further, into 1 of 5 broad core outcome areas—mortality, clinical/physiological, functioning/life impact, resource use, and adverse events based on a recently published taxonomy for outcomes in medical research.3

Results

Participants

The study flowchart is presented in Figure 1. We interviewed 13 pregnant women, 10 of whom were interviewed individually and 3 along with their family members (all of whom were spouses). The HCPs represented Canada, the Netherlands, the United Kingdom, and the United States. The demographic characteristics of all participants are presented in Table 1.

Interpretive analysis

In keeping with our study’s primary aim, our primary analysis involved translating quotes, anecdotes, experiences, and perspectives into measurable outcomes. Although the analytical process was identical for both HCP and patient/family member interviews, the latter relied quite heavily on interpretive analysis, because the concept of “outcomes” was less easily understood. Some quotes explicitly contained measurable outcomes and were easily translated. For example, “It’s still a big issue … just kind of like overwhelming anxiety sometimes, I am worrying constantly…,” which was translated to “maternal anxiety,” and “there was like a bit of concern when my son was born that I may have passed my condition on to him,” which was translated to “genetic transmission of maternal condition.” In some other cases, the outcome had to be deduced. For example, “I think once I gave birth I kind of fell off the radar … I had my 6-week appointment, but I feel like aftercare is kind-of dismissed” was translated to “maternal follow-up after childbirth,” whereas “I kind-of debated on taking the beta blockers after (the doctor) mentioned that the baby might be smaller” and “to have any type of medication in my system that will somehow go in utero to my child or, in any way affect his or her development and, while the baby would be exposed to a certain amount of it… it would be a very small amount but even that I am not comfortable with and, if I can do anything else before this I, I really see this as a last resort” were translated to “effect of medication on fetal development.” Not all experiences from these interviews could be translated into outcomes. Through this process, 17 unique outcomes were retrieved from the patient and family member interviews. HCP interviews, in contrast, seldom required the use of interpretive analysis and provided 45 unique outcomes. All these outcomes, taxonomized by core outcome areas, are presented in Table 2.

In keeping with our secondary aims, we first compared core outcome areas represented by interviews with patients and family members vs HCPs. The outcomes most frequently reported by the 13 sets of interviews involving patients and family members were related to general health and well-being
of fetus/baby (n = 13, 100%), congenital defects in baby (n = 6, 46%), stress/anxiety/mental health/fatigue (n = 5, 38%), and appropriate health care management, which included medications, follow-up, and continuity of care (n = 4, 31%). Although outcomes generated through individual patient interviews and joint interviews with family members were identical, family members (spouses) expressed a greater concern for maternal health over fetal health. In contrast, the most commonly reported outcomes by the 10 HCPs were thromboembolism (n = 10, 100%), arrhythmias (n = 9, 90%), new-onset or worsening heart failure (n = 9, 90%), prematurity and associated complications including cerebral palsy or respiratory difficulties (n = 8, 80%), maternal mortality (n = 7, 70%), and mode of delivery (n = 6, 60%). No appreciable differences were noted in the outcomes provided from HCPs of different geographic origins, nor were there appreciable differences in outcomes from the various medical specialties, apart from a greater emphasis on the respective field of specialization.

We finally compared the outcomes obtained through this study, with those obtained from our systematic review of published studies (unpublished data, 2020). As shown in Table 3, none of the 148 identified in the systematic review of clinical studies were related to the core outcome area of “life impact,” whereas 132 of 148 (94%) were related to the clinical outcomes and adverse events and 3 of 148 (2%) were related to resource use. In contrast, 13 of 17 (76.5%) of the outcomes obtained from the interviews were clinical or adverse event-related outcomes, 3 of 17 (17.6%) were related to life impact, and none were related to resource use.

**Discussion**

This study, conducted as part of developing a core outcome set for studies on cardiac disease in pregnancy, identified 17 unique outcomes reported by patients and family members, and 45 outcomes identified by HCPs. These outcomes represented all 5 core outcome areas, which include mortality/survival, clinical/physiological, adverse events, resource use, and life impact/functioning, the last area of which is not represented in published research on heart disease and pregnancy. In addition to providing patient- and stakeholder-reported outcomes for the purpose of developing a core outcome set and informing future research, this study highlights the importance of including PROs in studies on pregnancy and heart disease, to truly reflect benefits and harms or interventions, from a patient-centric perspective.

---

**Table 1. Characteristics of participants**

| Pregnant women with cardiac disease (n = 13)* | Health care providers (n = 10) |
|---------------------------------------------|---------------------------------|
| **Age** | 34 ± 4 y (range, 26-40 y) | **Role** |
| **Employment** | Employed full time (n = 7, 53.8%) | Cardiologist (n = 5, 50%) |
| | Self-employed (n = 2, 15.4%) | Obstetrician/maternal-fetal medicine physician (n = 3, 33.3%) |
| | Employed part time (n = 1, 7.7%) | Anaesthesiologist (n = 1, 10%) |
| | Homemaker (n = 1, 7.7%) | Cardiologist nurse practitioner (n = 1, 10%) |
| **Education** | Postgraduate degree (n = 2, 15.4%) | **Region, Country** |
| | Undergraduate degree (n = 5, 38.5%) | Toronto, Ontario, Canada (n = 5, 50%) |
| | College diploma (n = 6, 46.2%) | London, Ontario, Canada (n = 1, 10%) |
| **Ethnicity** | Caucasian (n = 8, 61.5%) | Vancouver, British Columbia, Canada (n = 1, 10%) |
| | South Asian (n = 2, 15.4%) | California, USA (n = 1, 10%) |
| | East Asian (n = 1, 7.7%) | Amsterdam, The Netherlands (n = 1, 10%) |
| | African or Afro-Caribbean (n = 2, 15.4%) | London, UK (n = 1, 10%) |
| **Gestational age** | 29 ± 7 wk (range, 16-37 wk) | |
| **Cardiac disease** | Complex congenital heart disease (n = 4, 31.0%) | |
| | Valvular heart disease (n = 2, 15.4%) | |
| | Electrical heart disease (n = 6, 46.2%) | |
| | Ischaemic heart disease (n = 1, 7.7%) | |

*Ten pregnant women with cardiac disease participated in individual interviews and 3 in shared interviews with their spouses.

---

**Figure 1.** Study flowchart.
| Core outcome area                        | Pregnant women and family members (n = 13) | Health care providers (n = 10) |
|-----------------------------------------|-------------------------------------------|--------------------------------|
| Mortality/survival                      | (1) Maternal mortality (n = 1)             | (1) Maternal mortality (n = 8) |
|                                         | (2) Short-term survival (n = 1)            | (2) Short-term survival (n = 1) |
|                                         | (3) Shorter life expectancy (n = 1)        | (3) Shorter life expectancy (n = 1) |
| Physiological/clinical outcomes         |                                           |                                |
| Cardiac                                 | (2) Arrhythmias (n = 4)                    | (4) Heart failure—new onset or worsening (n = 9) |
|                                         | (3) Heart failure (n = 2)                  | (5) Arrhythmias (n = 9)         |
|                                         | (4) Deterioration of cardiac/general condition (n = 2) | (6) Deterioration of valvular function (n = 6) |
|                                         | (5) Appropriate management of medications (n = 1) | (7) Pulmonary hypertension—worsening or resistant (n = 5) |
|                                         | (6) Syncope (n = 1)                        | (8) Myocardial ischemia (n = 5) |
|                                         |                                           | (9) Persisting or declining left ventricular function (n = 4) |
|                                         |                                           | (10) Heart transplant rejection (n = 4) |
|                                         |                                           | (11) Worsening of cardiomyopathy in current or subsequent pregnancy (n = 3) |
|                                         |                                           | (12) Aortic root dilation (n = 3) |
|                                         |                                           | (13) Aortic dissection (n = 2) |
|                                         |                                           | (14) Deterioration in New York Heart Association functional class (n = 2) |
|                                         |                                           | (15) Exacerbation of symptoms of coronary disease during and after pregnancy (n = 2) |
|                                         |                                           | (16) Deterioration of Fontan circulation (n = 1) |
|                                         |                                           | (17) Angina (n = 1) |
|                                         |                                           | (18) Aortic aneurysm (n = 1) |
|                                         |                                           | (19) Aortic rupture (n = 1) |
|                                         |                                           | (20) Risk of intervention for aortopathy (n = 1) |
|                                         |                                           | (21) Reversal of intracardiac shunt (n = 1) |
|                                         |                                           | (22) Need for cardiac intervention in pregnancy (n = 1) |
|                                         |                                           | (23) Congenital defects in baby (n = 4) |
|                                         |                                           | (24) Fetal growth concerns (n = 10) |
|                                         |                                           | (25) Prematurity and associated complications (n = 9) |
|                                         |                                           | (26) Fetal loss including miscarriage (n = 8) |
|                                         |                                           | (27) Mode of delivery (n = 6) |
|                                         |                                           | (28) Hypertensive disorders in pregnancy (n = 3) |
|                                         |                                           | (29) Healthy pregnancy and healthy baby (n = 1) |
|                                         |                                           | (30) Compromised placental circulation (n = 1) |
|                                         |                                           | (31) Pregnancy termination (n = 1) |
|                                         |                                           | (32) Thromboembolism (n = 10) |
|                                         |                                           | (33) Haemorrhage (n = 6) |
|                                         |                                           | (34) Stroke (n = 2) |
|                                         |                                           | (35) Future infertility (n = 1) |
|                                         |                                           | (36) Adverse events during labour and delivery (n = 3) |
|                                         |                                           | (37) Adverse effects of anticoagulants (n = 3) |
|                                         |                                           | (38) Warfarin-induced congenital defects (n = 2) |
|                                         |                                           | (39) Adverse events due to medication in general (n = 2) |
|                                         |                                           | (40) Adverse anaesthetic events (n = 1) |
|                                         |                                           | (41) Adverse events due to cardiac intervention (n = 1) |
|                                         |                                           |                                |
| Congenital, familial, and genetic       | (7) Congenital defects in baby (n = 6)     |                                |
| Pregnancy, puerperium, and perinatal    | (8) General health and well-being of baby (n = 13) |                                |
|                                         | (9) Healthy pregnancy/general wellness (n = 5) |                                |
|                                         | (10) Health and recovery after childbirth (n = 3) |                                |
|                                         | (11) Fetal growth concerns (small or large for gestational age) and overall birth weight (n = 4) |                                |
|                                         | (12) Gestational diabetes (n = 1)           |                                |
|                                         | (13) Mode of delivery: vaginal vs caesarean (n = 1) |                                |
| Other clinical outcomes                 | (14) Adverse effects of medication on fetal growth and development (n = 3) |                                |
|                                         | (15) Stress/anxiety/mental health/fatigue (n = 5) |                                |
| Functioning                             | (16) Quality of life/maintaining day-to-day functioning in pregnancy (n = 2) |                                |
|                                         | Delivery of care (17) Appropriate health care management (through medications, follow-up, continuity of care) (n = 4) |                                |
| Resource use                            |                                           | (45) Intensive care unit admission—mother or baby (n = 2) |

Studies specifically aimed at eliciting outcomes from patients and stakeholders involved in their care are now being widely seen as an integral part of developing core outcome sets, to inform future research. This is especially true for obstetric conditions and has been the focus of the OROS group. Meta-syntheses of qualitative studies, which are conducted to elicit experiences and perceptions on varying aspects of care, and not with the primary intent of obtaining outcomes for purposes of informing future research, are not ideal for obtaining PROs. Patient and stakeholder interviews
which enable researchers to obtain first-hand information from those directly affected by a condition and proposed interventions, and about how they would prioritize outcomes while making medical decisions, have therefore been the focus of recent publications.\textsuperscript{15-18} While conducting these interviews, in keeping with the primary intention of eliciting outcomes, attention must be paid to the use of a semi-structured interview guide and the liberal use of prompts to redirect patients and family members to focus on outcomes. Interpretive analysis, wherein quotes, anecdotes, experiences, and perceptions are translated into measurable outcomes, forms an integral part of the research process, especially for patient interviews, as the concept of outcomes can be difficult to explain and discuss with those who do not work and think in a health intervention context.\textsuperscript{11,12}

In our study, we found that although both groups of participants considered clinical/physiological outcomes (which included adverse events) related to their cardiac condition and pregnancy, importantly, they also commented on the importance of outcomes related to life impact and functioning, such as physical, emotional, and role functioning, as well as global quality of life and care delivery. In general, patients and family members favoured holistic health outcomes over specific clinical outcomes. Family members tended to show a greater preference for maternal health over fetal health, when compared with pregnant women, who prioritized the health of their babies equally, if not over, their own health. HCPs seemed to put a greater emphasis on maternal mortality, mode of delivery, adverse effects of treatment, and resource use, whereas the primary focus of patients and family members was the general well-being and health of the baby, mental health, and avoiding congenital malformations. Between HCPs, although there seemed to be consensus on outcomes they considered important, each specialist (cardiologist vs obstetrician vs anesthesiologist) emphasized outcomes related to their field of expertise. These differences highlight how patients, family members, and stakeholders differ in how they prioritize outcomes, all of which should ideally be represented in clinical research.

An important finding is that published studies tend to emphasize mostly clinical/physiological outcomes (including adverse events), with 94\% of the 148 unique outcomes identified in our systematic review, belonging to this core outcome area (unpublished data, 2020). Thus outcomes considered important by patients and stakeholders, belonging to the other core areas, especially life impact/functioning and resource use, are underrepresented in published research. For example, outcomes related to stress, anxiety, and mental health, reported as important by 5 of 13 patients, and quality of life, reported by 2 of 13 patients and 1 HCP, were not reported in a single one of the 409 studies on heart disease and pregnancy, included in the systematic review. Incorporating these patient- and stakeholder-reported outcomes in future research on pregnancy in cardiac disease is vital in this era of patient-centred care, and is the focus of COSCarP, which aims to ensure that outcomes reported in studies on cardiac diseases in pregnancy are not just restricted to treating cardiac pathology and improving specific pregnancy outcomes but include the psychosocial and functional dimensions of health and not just the absence of infirmity.

This paper has several strengths and implications for future research. This is the first study to focus on eliciting from pregnant women with cardiac disease, their family members and care providers, outcomes that they consider important, and which should therefore be measured in clinical trials. Health service users included not only a diverse group of patients, in terms of their demographics, and nature of heart disease, but also family members, adding an additional dimension to the health service user perspective. HCPs similarly included cardiologists, obstetricians, maternal-fetal medicine physicians, an anaesthesiologist, and a specialist nurse, with expertise in the management of pregnant women with heart disease, and represented 4 countries in Europe and North America. As this study was designed specifically to elicit outcomes, our choice of using interpretive analysis has further strengthened the focus and elicitation of outcomes. Having previously conducted a systematic review on this topic, we were able to draw comparisons between outcomes considered important by 3 important stakeholder groups—patients and clinicians in this study vs researchers in the systematic review, and to show how published studies do not report on core outcome areas such as life impact, functioning, mental health, and delivery of care considered important by patients with cardiac disease.

Despite these strengths, our study had a number of limitations that are important to acknowledge. The first is that for purposes of this paper, we did not conduct thematic analysis to further explore the patient experience and the reasons behind their perspectives. This was intentional, but this was also not required, because a meta-synthesis of (thematicaly analyzed) qualitative studies on experiences of pregnant women with cardiac diseases has been recently published.\textsuperscript{7} Second, although we gathered international representation for HCPs, patients and their family members were all recruited from a multidisciplinary clinic in Toronto, Canada. We acknowledge that although Toronto is among the most multicultural cities in the world, and our centre serves a large proportion of women from diverse socio-economic, ethnic, and other demographic backgrounds, Canada is still a resource-rich setting and it is possible that in resource-poor settings, outcomes and experiences may be different for patients and their family members. This was done for

| Core outcome areas          | Pregnant woman and family members (n = 17 outcomes) | Health care providers (n = 45 outcomes) | Systematic review of published studies (n = 148 outcomes) | P value |
|-----------------------------|-----------------------------------------------------|----------------------------------------|-----------------------------------------------------------|---------|
| Mortality and survival      | n = 1 (5.9\%)                                       | n = 3 (6.7\%)                          | n = 6 (4\%)                                               | > 0.99  |
| Clinical outcomes and adverse events | n = 13 (76.5\%)                                   | n = 33 (73.4\%)                        | n = 139 (94\%)                                            | 0.03    |
| Functioning/life impact     | n = 3 (17.6\%)                                     | n = 3 (6.7\%)                          | n = 0 (0\%)                                               | < 0.0001|
| Resource use                | n = 0 (0\%)                                        | n = 1 (2.2\%)                          | n = 3 (2\%)                                               | > 0.99  |
purposes of practicality, to get an in-depth idea of what patient and stakeholder outcomes might have been missed in published studies. However, this study is not the only source for incorporating patient perspectives into the core outcome set, as we intend to recruit patients globally for an online Delphi survey, in the near future, which will enable patients and HCPs from around the world to add to the long list of outcomes that we have obtained through the systematic review and these interviews. Third, despite the use of interpretive analysis, some participant experiences were difficult to convert into measurable outcomes and were therefore placed under the most appropriate core outcome area, which may have diluted or oversimplified the participant’s original statement. Another limitation is that patient-centred care research typically should include patients at all stages of research including design, analysis, interpretation, and knowledge translation. Although researchers did not include patients in the design aspect of the COSCarP study, this far, patients will be involved in the planning, interpretation, and analysis of subsequent steps, which include the Delphi process and a consensus meeting. Finally, an important concern about any form of qualitative research is reflexivity, the contextual intersecting relationships between the participants and themselves. During the process of planning and conduct of the study, the researchers were aware of their own positions and how this could influence the study and results. The interview guide was designed with the help of qualitative researchers, with only contextual input from the COSCarP investigators. Interviews were audio-recorded and transcribed verbatim, by an independent, professional medical transcriptionist. Transcripts were analyzed by the researcher who conducted the interviews. COSCarP investigators were not involved in their conduct or analysis, except for minimal involvement by the senior author in case of uncertainties. These measures notwithstanding, we acknowledge that some interpretation of data that have been drawn may be influenced by the views and bias of the researchers.

Conclusion

Through the conduct of in-depth interviews with 13 pregnant persons with cardiac disease, 3 family members, and 10 HCPs, this study identified 17 unique PROs and 45 outcomes reported by HCPs involved in their care. Although the specific outcomes differed between patients and HCPs, both groups reported as important outcomes related to life impact, in addition to mortality, adverse events, and clinical outcomes, which is the focus of published research in the field. It is important that future studies on pregnancy and cardiac disease report on outcomes considered important by patients and relevant stakeholders. To facilitate this, COSCarP is in the process of arriving at international consensus on a minimum standardized list of outcomes that must be reported in all studies on pregnancy and cardiac disease, and these interviews will go a long way in ensuring that patient- and stakeholder-reported outcomes are considered in the final core outcome set.

Acknowledgements

The authors would like to acknowledge all participants—patients, family members, and health care professionals, Amanda Urquhart for her assistance with transcribing the interviews, members of the OROS lab for their input in the development of the interview guide and study design, the COSCarP investigators for their input into various steps of developing the core outcome set, and Dr Rizwana Ashraf for her editorial assistance.

Funding Sources

This project was made possible through the Tolnai grant, Mount Sinai Hospital, Toronto, Canada, awarded to R.D.D. in June 2018.

Disclosures

R.D.D. has received speaking honoraria and research grants from Ferringo, Canada, for projects on induction of labour, which are not related to COSCarP. C.H. has no conflicts of interest to disclose.

References

1. Elkayam U, Goland S, Pieper PG, Silversides CK. High-risk cardiac disease in pregnancy: part I. J Am Coll Cardiol 2016;68:396-410.
2. Knight M, Nair M, Tuffnell D, et al. Saving Lives, Improving Mothers’ Care—Lessons Learned to Inform Maternity Care from the UK and Ireland Confidential Enquiries into Maternal Deaths and Morbidity 2013–15. Oxford, UK: MBRRACE-UK, National Perinatal Epidemiology Unit, University of Oxford, 2017.
3. Dodd S, Clarke M, Becker L, et al. A taxonomy has been developed for outcomes in medical research to help improve knowledge discovery. J Clin Epidemiol 2018;96:84-92.
4. Kirkham JJ, Davis K, Altman DG, et al. Core outcome set-STATards for Development: the COS-STAT recommendations. PLoS Med 2017;14:e1002447.
5. Williamson PR, Altman DG, Bagley H, et al. The COMET Handbook: version 1.0. Trials 2017;18(Suppl 3):280.
6. D’Souza R, Hall C, Sermer M, Siu S, Silversides C. Development of a core outcome set for studies on cardiac disease in pregnancy (COSCarP): a study protocol. Trials 2020;21:300.
7. Dawson AJ, Krastev Y, Parsonage WA, et al. Experiences of women with cardiac disease in pregnancy: a systematic review and metasynthesis. BMJ Open 2018;8:e022755.
8. D’Souza R, Sermer M, Silversides CK. Pregnancy in women with congenital heart disease. Obestet Med 2015;8:18-25.
9. D’Souza R; OROS Investigators. Outcome Reporting in Obstetric Studies (OROS) Project. Available at: https://www.obgyn.utoronto.ca/oros-project. Accessed February 14, 2020.
10. Dadouch R, Hall C, Du Mont J, D’Souza R; OROS investigators. Obesity in pregnancy—patient-reported outcomes in qualitative research: a systematic review. J Obestet Gynaecol Can 2020;42:1001-11.
11. Keeley T, Williamson P, Gallyp P, et al. The use of qualitative methods to inform Delphi surveys in core outcome set development. Trials 2016;17:230.
12. Kaufman J, Ryan R, Hill S. Qualitative focus groups with stakeholders identify new potential outcomes related to vaccination communication. PloS One 2018;13:e0201145.
13. D’Souza R, Shah PS, Sander B. Clinical decision analysis in perinatology. Acta Obstet Gynecol Scand 2018;97:491-9.

14. Pope C, Mays N, Popay J. Synthesizing Qualitative and Quantitative Health Evidence: A Guide to Methods. New York: Open University Press, 2007.

15. Dadouch R, Faheim M, Juando-Prats C, et al. Development of a core outcome set for studies on obesity in pregnant patients (COSSOPP): a study protocol. Trials 2018;19:655.

16. Duffy JMN, Hirsch M, Ziebland S, McManus RJ. International Collaboration to Harmonise Outcomes in Pre-eclampsia (iHOPE). Methodological decisions influence the identification of potential core outcomes in pre-eclampsia related studies: a sensitivity analysis informing the development of guidelines for future core outcome set developers. BJOG 2019;126:1482-90.

17. King A, D’Souza R, Teshler L, N S, Malinowski A. The development of a core outcome set for studies on perinatal venous thromboembolism (COSPVenTE): a study protocol. BMJ Open 2020;10: e034017.

18. D’Souza R, Villani L, Hall C, et al. Core outcome set for studies on pregnant women with vasa previa (COVaSP): a study protocol. BMJ Open 2020;10:e034018.

19. Dodgson JE. Reflexivity in qualitative research. J Hum Lact 2019;35: 220-2.

Supplementary Material
To access the supplementary material accompanying this article, visit CJC Open at https://www.cjcopen.ca/ and at https://doi.org/10.1016/j.cjco.2020.05.010.